Back to top
more

Bristol Myers Squibb (BMY)

(Real Time Quote from BATS)

$55.59 USD

55.59
1,156,600

+1.27 (2.34%)

Updated Nov 4, 2024 10:22 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Company News for Nov 1, 2024

by Zacks Equity Research

Companies In The Article Are: MET,CI, BMY, MO

Is SPDR Russell 1000 Low Volatility Focus ETF (ONEV) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for ONEV

Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View

by Zacks Equity Research

BMY posts impressive third-quarter results, with both earnings and sales beating the respective estimates. The company also raises its annual earnings guidance.

Initial Claims Lower-Than-Expected

by Zacks Equity Research

Initial Claims Lower-Than-Expected

Mark Vickery headshot

Un-spooky Halloween: PCE, Jobless Claims Tame

by Mark Vickery

It's hard to wish for a more in-line PCE report, especially considering it's the preferred print on inflation for the Fed.

Compared to Estimates, Bristol Myers (BMY) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Bristol Myers Squibb (BMY) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Bristol Myers (BMY) delivered earnings and revenue surprises of 20.81% and 5.07%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Mark Vickery headshot

Markets Give Back Gains as Hovering Continues

by Mark Vickery

As we've stated in this space previously, the big news the market is waiting for is not here yet.

Should VanEck Morningstar Wide Moat ETF (MOAT) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for MOAT

Pfizer's Q3 Earnings Beat, Paxlovid Drives Sales Guidance Increase

by Zacks Equity Research

PFE beats third-quarter estimates for earnings and sales. It raises 2024 earnings and revenue expectations.

Will Non-COVID Drugs Again Boost Pfizer's Top Line in Q3 Earnings?

by Zacks Equity Research

Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the third quarter.

Ekta Bagri headshot

Should Bristol Myers Stock Be in Your Portfolio Pre-Q3 Earnings?

by Ekta Bagri

BMY is looking to turnaround its business, banking on the strong uptake of new drugs. The recent spate of positive regulatory updates also bodes well for the stock, and we recommend it to investors.

Will These 5 Big Drug Stocks Surpass Q3 Earnings Forecasts?

by Zacks Equity Research

Let's look at five pharma and drug companies, PFE, LLY, ABBV, MRK and BMY, that are scheduled to release their third-quarter 2024 results this week.

Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Myriad (MYGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Curious about Bristol Myers (BMY) Q3 Performance? Explore Wall Street Estimates for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Bristol Myers (BMY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) concluded the recent trading session at $52.92, signifying a -0.26% move from its prior day's close.

Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock

by Zacks Equity Research

Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Bristol Myers (BMY) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Bristol Myers (BMY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BMY or VRTX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

BMY vs. VRTX: Which Stock Is the Better Value Option?

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Bristol Myers Squibb (BMY) Dips More Than Broader Market: What You Should Know

by Zacks Equity Research

The latest trading day saw Bristol Myers Squibb (BMY) settling at $53.18, representing a -0.36% change from its previous close.

Wave Life Sciences (WVE) Moves 74.1% Higher: Will This Strength Last?

by Zacks Equity Research

Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Exelixis Gets Favorable Ruling in Patent Litigation With MSN

by Zacks Equity Research

The Delaware District Court ruled in EXEL's favor, rejecting MSN's challenge to three patents related to cabozantinib.

Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC

by Zacks Equity Research

EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively.